Starting Your Journey with Endometrial Cancer

A diagnosis of endometrial cancer can feel overwhelming, but it is important to know that you are not alone and that this is a highly treatable condition. This condition occurs when cells in the endometrium—the inner lining of the uterus—begin to grow out of control ^[1]. Because it often causes early symptoms like unusual bleeding, many cases are caught in the beginning stages when the condition is most treatable ^[1].

Understanding Your Diagnosis

Endometrial cancer is the most common cancer of the female reproductive system in high-income countries ^[2]. While it can happen at any age, it is most frequently diagnosed in postmenopausal women ^[1].

The general prognosis for endometrial cancer is encouraging, especially when localized. While survival statistics are population estimates—not a personal guarantee—they show that early detection leads to better outcomes:

• Stage I: The 5-year relative survival rate is historically greater than 86% ^[1].
• Stage II: The 5-year relative survival rate is greater than 75% ^[1].
• Stage III & IV: While these stages are more advanced, survival rates are improving with new targeted treatments and immunotherapies, though historically they range from roughly 18% to 41% depending on how far the cancer has spread ^[1].
  It is important to remember that these statistics vary by country, histology, and molecular subtype, and may not reflect the newest molecularly guided treatments.

Biological Risk Factors

It is common to look for reasons why cancer happens. It is important to understand that many risk factors are biological processes that are not within your direct control. Researchers focus on these factors to understand how the cancer develops, not to assign blame.

• Hormonal Balance: The endometrium is sensitive to estrogen, which promotes cell growth. “Unopposed estrogen” occurs when there is estrogen without enough progesterone (the hormone that balances it) to signal the lining to shed or stop growing ^[3]. This can happen due to chronic irregular ovulation, conditions like PCOS, certain medications (like estrogen-only hormone therapy), or obesity. Menopause itself lowers both estrogen and progesterone, but fat tissue contains an enzyme called aromatase that can continue to convert other hormones into estrogen after menopause ^[3].
• Metabolic Factors: Conditions like obesity and type 2 diabetes are linked to risk through complex biology. In fat tissue, aromatase converts other hormones into estrogen ^[3]. Additionally, high levels of insulin (hyperinsulinemia) can act as a growth signal for endometrial cells ^[4].
• Age: Like many cancers, the risk increases as we age because cells have had more time to undergo changes ^[1].

The New Standard: Molecular Classification

In the past, doctors looked only at how cells appeared under a microscope (histology). Today, the international standard has shifted to molecular classification ^[5]. This means looking at the “fingerprint” of the tumor’s DNA to predict how it will behave and which treatments will work best.

Your doctor will likely categorize your cancer into one of four groups:

1. POLE-mutated: These tumors often look aggressive but usually have an excellent prognosis and may require less intensive treatment ^[6][7].
2. MMRd (Mismatch Repair Deficient): These tumors have trouble repairing DNA errors. They often respond very well to immunotherapy ^[8].
3. NSMP (No Specific Molecular Profile): This is a common group where the tumor doesn’t have the other specific markers; treatment is based on traditional factors like stage and grade ^[6].
4. p53-abnormal: These tumors tend to be more aggressive and usually require more intensive treatment, such as chemotherapy combined with radiation ^[6][9].

The FIGO 2023 staging system now uses these molecular results to refine your stage. For example, a POLE mutation can actually “downstage” a tumor because the outlook is so favorable ^[5].

Addressing Racial Disparities

Research has identified significant disparities in how endometrial cancer affects different communities. While Black and White women are diagnosed at similar overall rates when accounting for hysterectomy prevalence, Black women are more than twice as likely to die from the disease ^[1].

This disparity is driven by a combination of factors:

• Aggressive Subtypes: Black women are more likely to be diagnosed with aggressive versions of the disease, such as serous carcinoma or carcinosarcoma ^[10][11].
• Systemic Barriers: Even when the cancer type is the same, Black women may face differences in the quality of care they receive, structural barriers, or delays in diagnosis ^[12].

Acknowledging these facts helps patients and doctors partner to ensure timely specialist referrals, equitable access to molecular testing, and appropriate, individualized care. Follow-up and treatment intensity should be based on your specific tumor biology and clinical needs, not assumed by race.

What Research Is Still Exploring

While we have made great strides, some areas remain uncertain. Doctors are still working to determine the best treatment for rare subtypes like clear-cell carcinoma ^[13]. There is also ongoing research into “de-escalation”—finding out if appropriately selected patients can safely have less treatment (like avoiding radiation) if their molecular profile is very low-risk ^[14]. Your care team will use the best current evidence to guide your specific journey.